Keywords: Kineret, Amgen, Inflammatory genetic disorder, NIOMID, NIH

Kineret halts organ damage in inflammatory genetic disorder

Article | 13 February 2012

Print This

A new study shows that Kineret (anakinra), a drug developed by US biotech giant Amgen (Nasdaq: AMGN) approved in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in